breakthrough infections – Page 5 – Communicable Diseases Research

Clinical and genomic signatures of SARS-CoV-2 Delta breakthrough infections in New York

뉴욕에서 SARS-CoV-2 Delta 획기적인 감염의 임상 및 게놈 서명

Article

Published on 2022-08-012022-09-11
Journal: EBioMedicine [Category] COVID19(2023년), SARS, 변종, 유전자 메커니즘,

Evaluating clinical effectiveness of SARS-CoV-2 vaccine in solid organ transplant recipients: A propensity score matched analysis

고형장기 이식 환자에서 SARS-CoV-2 백신의 임상 효과 평가: 성향 점수 일치 분석

Article

Published on 2022-08-012022-09-11
Journal: Transplant infectious disease : an official journa [Category] COVID19(2023년), SARS, 변종,

Limited neutralisation of the SARS-CoV-2 Omicron subvariants BA.1 and BA.2 by convalescent and vaccine serum and monoclonal antibodies

회복기 및 백신 혈청 및 단일 클론 항체에 의한 SARS-CoV-2 오미크론 하위 변이체 BA.1 및 BA.2의 제한된 중화

Article

Published on 2022-08-012022-09-11
Journal: EBioMedicine [Category] COVID19(2023년), MERS, SARS, 변종, 진단,

[키워드] ACE2 addition antibody BA.1 BA.2 BNT162b2 booster booster dose booster vaccination breakthrough infections Casirivimab Cell Complete convalescent convalescent sera Delta dominant dose education Efficacy elicited exhibited expressing Frankfurt Imdevimab Immunity in vitro study individual infection with SARS-CoV-2 Limited majority median monoclonal antibodies monoclonal antibody monoclonal antibody therapy Mutation neutralisation neutralise neutralising neutralizing capacity omicron Omicron variants reduced Region SARS-CoV-2 sera serum Sotrovimab specific resistance Spike protein supported tested the SARS-CoV-2 the spike protein therapy TMPRSS2 university vaccination Vaccine Vaccines variants variants of SARS-CoV-2 waning immunity
[DOI] 10.1016/j.ebiom.2022.104158 PMC 바로가기 [Article Type] Article

Levels of SARS-CoV-2 antibodies among fully vaccinated individuals with Delta or Omicron variant breakthrough infections

Delta 또는 Omicron 변이형 돌발성 감염이 있는 완전 예방접종을 받은 개인의 SARS-CoV-2 항체 수준

Observational Study

Published on 2022-08-012022-09-11
Journal: Nature Communications [Category] SARS, 변종, 임상, 진단, 치료법,

Humoral and cellular responses to mRNA-based COVID-19 booster vaccinations in patients with solid neoplasms under active treatment

Article

Published on 2022-08-012022-10-05
Journal: ESMO open [Category] 진단, 치료법,

[키워드] acute respiratory syndrome anti-spike antibody antibodies baseline BNT162b2 booster booster dose booster vaccination breakthrough infections Cancer cancer patient Cancer patients Care cause CD19+ CD4+ cell counts Cellular immune response cellular immunity cellular response Chemotherapy coronavirus COVID-19 COVID-19 infection died disease dose Efficacy Endocrine evaluated excluded exclusion criteria Factor Factors high risk high-risk population hospital humoral Humoral immunity immune response Immunosuppression immunosuppressive Infection Messenger RNA Mild mRNA mRNA vaccine mRNA-1273 mRNA-based neoplasm neutralizing antibody older patients Other outcome overcome Patient positive reduced required Result severe coronavirus disease significant increase significantly increased significantly lower solid malignancy solid tumors T-cell Response treated Treatment vaccination Vaccine vaccine dose Vaccines were assessed
[DOI] 10.1016/j.esmoop.2022.100587 [Article Type] Article

Dynamics of antibody titers and cellular immunity among Japanese healthcare workers during the 6 months after receiving two doses of BNT162b2 mRNA vaccine

BNT162b2 mRNA 백신 2회 접종 후 6개월 동안 일본 의료 종사자의 항체 역가 및 세포 면역의 역학

Article

Published on 2022-07-302022-09-11
Journal: Vaccine [Category] COVID19(2023년), MERS, SARS, 진단, 치료법,

[키워드] All participant All participants Analysis antibody Antibody titer Antibody titers Asymptomatic BNT162b2 BNT162b2 mRNA BNT162b2 vaccine Breakthrough infection breakthrough infections Cellular immune response cellular immune responses cellular immunity clinical trial collected conducted COVID-19 determinant determinants determine dose Dynamics elevated follow-up period healthcare healthcare worker Healthcare workers humoral IgG immune response immune responses incidence Japanese knowledge medical condition Medical conditions mRNA vaccine mRNA vaccines Nucleocapsid proteins of BNT162b2 participant Pfizer Pfizer-BioNTech positive prospective cohort study receiving SARS-CoV-2 SARS-COV-2 infection SARS-CoV-2 vaccine seroconverted serum sample serum samples study period T-cell immune response T-cell immune responses timepoint vaccination Vaccine waned were measured within 6 months
[DOI] 10.1016/j.vaccine.2022.06.016 PMC 바로가기 [Article Type] Article

Origin, virological features, immune evasion and intervention of SARS-CoV-2 Omicron sublineages

SARS-CoV-2 오미크론 하위 계통의 기원, 바이러스학적 특징, 면역 회피 및 개입

Review

Published on 2022-07-192022-09-11
Journal: Signal Transduction and Targeted Therapy [Category] Coronavirus, COVID19(2023년), SARS, 변종, 진단, 치료제,

Different Neutralization Profiles After Primary SARS-CoV-2 Omicron BA.1 and BA.2 Infections

1차 SARS-CoV-2 Omicron BA.1 및 BA.2 감염 후 다른 중화 프로필

Article

Published on 2022-07-192022-09-11
Journal: Frontiers in Immunology [Category] COVID19(2023년), MERS, SARS, 변종, 진단, 치료기술,

[키워드] activity acute respiratory syndrome acute respiratory syndrome coronavirus acute respiratory syndrome coronavirus 2 antibody Antibody Response Antibody responses B.1.1.529 B.1.617.2 breakthrough infections contribute controls coronavirus cross-neutralization cross-neutralizing Delta detectable ENhance Humoral immunity Immune escape individual individuals infected individuals Infection lineages Live virus mRNA mRNA vaccination multiple exposures mutated naïve neutralization neutralization test neutralization tests Neutralizing antibodies neutralizing antibody omicron Omicron sub-lineages Omicron variants other variants pre-immune Primary infection profile reduced respiratory SARS-CoV-2 SARS-CoV-2 neutralization SARS-CoV-2 variant SARS-CoV-2 variant of concern SARS-CoV-2 variants serum Serum Neutralization serum sample serum samples severe acute respiratory syndrome Coronavirus specific neutralizing antibodies Spike protein Strains tested These data vaccinated individual vaccinated individuals Vaccination strategies Vaccination strategy Vaccinations variant variants wildtype
[DOI] 10.3389/fimmu.2022.946318 PMC 바로가기 [Article Type] Article

Immune responses in Omicron SARS-CoV-2 breakthrough infection in vaccinated adults

백신 접종 성인의 Omicron SARS-CoV-2 돌발성 감염의 면역 반응

Article

Published on 2022-07-182022-09-11
Journal: Nature Communications [Category] COVID19(2023년), MERS, SARS, 변종, 진단, 치료기술,

[키워드] activated antibody antigens B cell B cell response Breakthrough infection breakthrough infections Cell cells cellular immunity circulation Cytotoxic T cells de novo follicular functional humoral humoral responses Immunity individual Infection memory B cell memory B cells memory T memory T cell Mutation omicron participant plasmablast PROTECT Protein RBD-specific IgG recall Receptor binding domain response robust SARS-CoV-2 significantly increased spike Spike protein T cell T cell response T cell responses T cells the Spike Transmissibility vaccinated individuals vaccine immunity Vaccines variant Viral viral antigens viral escape wild type
[DOI] 10.1038/s41467-022-31888-y PMC 바로가기 [Article Type] Article

Codelivery of SARS-CoV-2 Prefusion-Spike Protein with CBLB502 by a Dual-Chambered Ferritin Nanocarrier Potentiates Systemic and Mucosal Immunity

이중 챔버 페리틴 나노 캐리어에 의한 CBLB502와 SARS-COV-2 프리 펜션-스파이크 단백질의 코드 전달은 전신 및 점막 면역을 강화시킨다.

Article

Published on 2022-07-182022-08-31
Journal: ACS applied bio materials [Category] COVID19(2023년), MERS, SARS, 변종, 진단, 치료제,

[키워드] activate acute respiratory syndrome acute respiratory syndrome coronavirus acute respiratory syndrome coronavirus 2 approved Breakthrough infection breakthrough infections CBLB502 Cellular immune response codelivery contribute coronavirus dual-chambered elevated Factor ferritin ferritin nanocarrier IL-4 immune response immune responses Immunity Immunoglobulin Immunoglobulin G immunoglobulin G response inefficient INF-γ injection intramuscular Lower respiratory tract moderate mucosal mutant prefusion prefusion-spike respiratory SARS-CoV-2 severe acute respiratory syndrome Coronavirus significantly systemic systemic and local systemic and mucosal immunity. Trigger upper and lower respiratory tract upper respiratory tract Vaccine Vaccine development variants of SARS-CoV-2
[DOI] 10.1021/acsabm.2c00328 PMC 바로가기 [Article Type] Article